Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1791MR)

This product GTTS-WQ1791MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1791MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8900MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ12782MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ14267MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ9880MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ12016MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ8844MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ11135MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ11789MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW